Evidence map›Paper›PMID 33803939›Full record

ArticleCancers2021

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines.

Setor Amuzu, Euridice Carmona, Anne-Marie Mes-Masson, Celia M T Greenwood, Patricia N Tonin, Jiannis Ragoussis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Setor AmuzuDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada.ORCID 0000-0003-3244-7475
Euridice CarmonaCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC H2X 0A9, Canada.
Anne-Marie Mes-MassonCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC H2X 0A9, Canada.ORCID 0000-0002-6498-266X
Celia M T GreenwoodDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada.ORCID 0000-0002-2427-5696
Patricia N ToninDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada.
Jiannis RagoussisDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada.
Centre Hospitalier de l’Université de Montréal · CAMcGill Genome Centre · CAJewish General Hospital · CAMcGill University Health Centre · CA

Funding

Canadian Queen Elizabeth II Diamond Jubilee PhD scholarship at McGill University 242146Cancer Research Society & Ovarian Cancer Canada 20087
6 · The paper itself

Abstract

The benefit of PARP inhibitor olaparib in relapsed and advanced high-grade serous ovarian carcinoma (HGSOC) is well established especially in

Indexed as

cancer cell linesgenomic markersolaparibPARP1

Identifiers

PMID33803939
PMCPMC7998846
OpenAlexW3135952602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.